Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.)
In the Namenda case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis’ memantine hydrochloride, sold under the brand name Namenda and Namenda XR. The complaint alleges that Actavis engaged in an illegal product hop to move the market from Namenda to Namenda XR in order to thwart competition from generic Namenda.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
685 Third Avenue 26th Floor
10017 New York, New York
Joseph T. Lukensjlukens@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Peter Kohnpkohn@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
685 Third Avenue 26th Floor New York, New York10017 (212) 983-9330 (877) 247-4292 (212) 983-9331
10866 Wilshire Boulevard Suite 1470 Los Angeles, California90024 (424) 256-2884 (424) 256-2885